Patrícia Fidelis de Oliveira

Patrícia Fidelis de Oliveira

Auto-generated profile, based on publicly available information

Patrícia Fidelis de Oliveira

Biosciences Institute of Botucatu, São Paulo State University, Botucatu, São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2017 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
APANDRE GONCALVES Prospero
ANDRE GONCALVES Prospero
CQCaio C. Quini
Caio C. Quini
ABAndris Bakuzis
Andris Bakuzis
PFPatrícia Fidelis-De-Oliveira
Patrícia Fidelis-De-Oliveira
GMGustavo M. Moretto
Gustavo M. Moretto
JMjose Ricardo Arruda Miranda
jose Ricardo Arruda Miranda
We introduce and demonstrate that the AC biosusceptometry (ACB) technique enables real-time monitoring of magnetic nanoparticles (MNPs) in the bloodstream. We present an ACB system as a simple, portable, versatile, non-invasive, and accessible tool to study pharmacokinetic parameters of MNPs, such as circulation time, in real time. We synthesized and monitored manganese doped iron oxide nanoparticles in the bloodstream of Wistar rats using two different injection protocols. Aiming towards a translational approach, we also simultaneously evaluated cardiovascular parameters, including mean arterial pressure, heart rate, and episodes of arrhythmia in order to secure the well-being of all animals. We found that serial injections increased the circulation time compared with single injections. Immediately after each injection, we observed a transitory drop in arterial pressure, a small drop in heart rate, and no episodes of arrhythmia. Although some cardiovascular effects were observed, they were transitory and easily recovered in both protocols. These results indicate that the ACB system may be a valuable tool for in vivo, real-time MNP monitoring that allows associations with other techniques, such as pulsatile arterial pressure and electrocardiogram recordings, helping ensuring the protocol safety, which is a fundamental step towards clinical applications.

1 December 2005 in Regulatory Peptides
Verified
Journal Article
Closed access
RCR.H. Costa-E-Sousa
R.H. Costa-E-Sousa
PPP.P. Pereira-Junior
P.P. Pereira-Junior
POP.F. Oliveira
P.F. Oliveira
EOE.L. Olivares
E.L. Olivares
JCJoao Pedro Werneck de Castro
Joao Pedro Werneck de Castro
Antonio Carlos Campos de CarvalhoAntonio Carlos Campos de Carvalho
Antonio Carlos Campos de Carvalho

2 February 2010 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Closed access
PDF file
RLRuy A. Louzada
Ruy A. Louzada
POPatricia F. Oliveira
Patricia F. Oliveira
JCJoao Paulo A. Cavalcanti-De-Albuquerque
Joao Paulo A. Cavalcanti-De-Albuquerque
LCLeandro Cunha-Carvalho
Leandro Cunha-Carvalho
MBMarcelo R. Baldanza
Marcelo R. Baldanza
JCJoao Pedro Werneck de Castro
Joao Pedro Werneck de Castro

1 September 2012 in Cell Transplantation
Verified
Journal Article
Closed access
LBLuiza L. S. Bagno
Luiza L. S. Bagno
JCJoao Pedro Werneck de Castro
Joao Pedro Werneck de Castro
POPatrícia F. Oliveira
Patrícia F. Oliveira
MCMárcia S. Cunha-Abreu
Márcia S. Cunha-Abreu
NRNazareth N. Rocha
Nazareth N. Rocha
Antonio Carlos Campos de CarvalhoAntonio Carlos Campos de Carvalho
Antonio Carlos Campos de Carvalho
Recent studies have identified adipose tissue as a new source of mesenchymal stem cells for therapy. The purpose of this study was to investigate the therapy with adipose-derived stromal cells (ASCs) in a rat model of healed myocardial infarction (MI). ASCs from inguinal subcutaneous adipose tissue of male Wistar rats were isolated by enzymatic digestion and filtration. Cells were then cultured until passage 3. Four weeks after ligation of the left coronary artery of female rats, a suspension of either 100 μl with phosphate-buffered saline (PBS) + Matrigel + 2 × 106 ASCs labeled with Hoechst ( n = 11) or 100 μl of PBS + Matrigel ( n = 10) was injected along the borders of the ventricular wall scar tissue. A sham-operated group ( n = 5) was submitted to the same surgical procedure except permanent ligation of left coronary artery. Cardiac performance was assessed by electro- and echocardiogram. Echo was performed prior to injections (baseline, BL) and 6 weeks after injections (follow-up, FU), and values after treatment were normalized by values obtained before treatment. Hemodynamic measurements were performed 6 weeks after injections. All infarcted animals exhibited cardiac function impairment. Ejection fraction (EF), shortening fractional area (SFA), and left ventricular akinesia (LVA) were similar between infarcted groups before treatment. Six weeks after therapy, ASC group showed significant improvement in all three ECHO indices in comparison to vehicle group. In anesthetized animals dp/dt+ was also significantly higher in ASCs when compared to vehicle. In agreement with functional improvement, scar area was diminished in the ASC group. We conclude that ASCs improve cardiac function in infarcted rats when administered directly to the myocardium.

1 March 2010 in Brazilian Journal of Medical and Biological Research
Verified
Journal Article
Open access
PDF file
VPV. Pinho-Ribeiro
V. Pinho-Ribeiro
AMA.C.V. Maia
A.C.V. Maia
JWJ.P S. Werneck-De-Castro
J.P S. Werneck-De-Castro
POP.F. Oliveira
P.F. Oliveira
Regina Coeli dos Santos GoldenbergRegina Coeli dos Santos Goldenberg
Regina Coeli dos Santos Goldenberg
Antonio Carlos Campos de CarvalhoAntonio Carlos Campos de Carvalho
Antonio Carlos Campos de Carvalho
Therapy with bone marrow-derived cells has been used in ischemic patients with reported success. The aim of this study was to determine the therapeutic efficacy of fresh and frozen human umbilical cord blood cells (hUCB) in Wistar rats submitted to permanent occlusion of the left coronary artery. Three hours after myocardial infarction, 2 x 10(7) hUCB cells or vehicle were administered by intramyocardial injection. The animals were divided into five groups: control (N = 10), sham operated (N = 10), infarcted that received vehicle (N = 9), infarcted treated with cryopreserved hUCB (N = 7), and infarcted treated with fresh hUCB (N = 5). Cardiac function was evaluated by electrocardiogram (ECG) and echocardiogram (ECHO) before cell therapy, and by ECG, ECHO, cardiopulmonary test, and left ventricular pressure measurements 3 weeks later. After 3 weeks, both groups treated with hUCB still had Q wave present in L1, âQRS >90 degrees and reduced shortening fraction (less than 50%). In addition, cardiac indexes of left ventricular contractility and relaxation were 5484 +/- 875 and -4032 +/- 643 mmHg (cryopreserved hUCB) and 4585 +/- 955 and -2862 +/- 590 mmHg (fresh hUCB), respectively. These values were not statistically different from those of saline-treated animals. Cardiopulmonary exercise test profile was typical of infarcted hearts; exercise time was about 14 min and maximal VO2 was 24.77 +/- 5.00 mL.kg-1.min-1. These data show that hUCB therapy did not improve the cardiac function of infarcted animals or prevent cardiac remodeling.

1 June 2005 in Brazilian Journal of Medical and Biological Research
Verified
Journal Article
Open access
PDF file
POP.F. Oliveira
P.F. Oliveira
VSV.J. Dias da Silva
V.J. Dias da Silva
MSM.C.O. Salgado
M.C.O. Salgado
RJR. Fazan Jr.
R. Fazan Jr.
CAC.A. Aguiar
C.A. Aguiar
HSH.C. Salgado
H.C. Salgado
The aim of the present study was to evaluate the effect of amiodarone on mean arterial pressure (MAP), heart rate (HR), baroreflex, Bezold-Jarisch, and peripheral chemoreflex in normotensive and chronic one-kidney, one-clip (1K1C) hypertensive rats (N = 9 to 11 rats in each group). Amiodarone (50 mg/kg, iv) elicited hypotension and bradycardia in normotensive (-10 ± 1 mmHg, -57 ± 6 bpm) and hypertensive rats (-37 ± 7 mmHg, -39 ± 19 bpm). The baroreflex index (deltaHR/deltaMAP) was significantly attenuated by amiodarone in both normotensive (-0.61 ± 0.12 vs -1.47 ± 0.14 bpm/mmHg for reflex bradycardia and -1.15 ± 0.19 vs -2.63 ± 0.26 bpm/mmHg for reflex tachycardia) and hypertensive rats (-0.26 ± 0.05 vs -0.72 ± 0.16 bpm/mmHg for reflex bradycardia and -0.92 ± 0.19 vs -1.51 ± 0.19 bpm/mmHg for reflex tachycardia). The slope of linear regression from deltapulse interval/deltaMAP was attenuated for both reflex bradycardia and tachycardia in normotensive rats (-0.47 ± 0.13 vs -0.94 ± 0.19 ms/mmHg and -0.80 ± 0.13 vs -1.11 ± 0.13 ms/mmHg), but only for reflex bradycardia in hypertensive rats (-0.15 ± 0.02 vs -0.23 ± 0.3 ms/mmHg). In addition, the MAP and HR responses to the Bezold-Jarisch reflex were 20-30% smaller in amiodarone-treated normotensive or hypertensive rats. The bradycardic response to peripheral chemoreflex activation with intravenous potassium cyanide was also attenuated by amiodarone in both normotensive (-30 ± 6 vs -49 ± 8 bpm) and hypertensive rats (-34 ± 13 vs -42 ± 10 bpm). On the basis of the well-known electrophysiological effects of amiodarone, the sinus node might be the responsible for the attenuation of the cardiovascular reflexes found in the present study